Predictors and Significance of Kidney Dysfunction in Patients with Chronic Graft-versus-host Disease

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2023 Jul 20

PMID 37474729

Authors

David Beshensky

Filip Pirsl

Noa G Holtzman

Seth M Steinberg

Jacqueline W Mays

Edward W Cowen

Leora E Comis

Galen O Joe

M Teresa Magone

Eduard Schulz

Meryl A Waldman

Steven Z Pavletic

Affiliations

Soon will be listed here.

Abstract

Kidney complications have been studied in allogeneic hematopoietic stem cell transplant patients but not specifically among chronic graft-versus-host disease (cGVHD) patients. Participants (n = 365) enrolled in the cross-sectional cGVHD natural history study (NCT00092235) were assessed for kidney dysfunction and overall survival. Kidney dysfunction was analyzed for associations in univariate and multivariable analyses. Kidney dysfunction (eGFR < 60) was found in 64 patients, and 29 patients had moderate-severe kidney dysfunction (eGFR < 45). Patients with kidney dysfunction were more likely treated with cyclosporine at evaluation or to have received it for GVHD prophylaxis, or prior treatment of GVHD. Patients with kidney dysfunction were less severely affected by cGVHD of skin, mouth, and joints/fascia. In multivariable modeling, history of cyclosporine use (OR = 2.19, 95% CI 1.13-4.25), angiotensin receptor blocker use (OR = 5.57, 95% CI 1.49-20.84), proteinuria (OR = 2.39, 95% CI 1.19-4.79), lower CRP (OR = 0.95, 95% CI 0.91-0.99), lower C3 (OR = 0.98, 95% CI 0.97-0.99), and lower hemoglobin (OR = 0.70, 95% CI 0.58-0.84) were jointly associated with kidney dysfunction. Overall survival was lower in those with moderate-severe kidney dysfunction (p = 0.015), demonstrating the importance of addressing kidney dysfunction in this population. The association of kidney dysfunction with less severe cGVHD suggests an etiology unrelated to cGVHD but potentially a consequence of drug-related toxicities.

References

Majhail N, Tao L, Bredeson C, Davies S, Dehn J, Gajewski J . Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transplant. 2013; 19(10):1498-501. PMC: 3779514. DOI: 10.1016/j.bbmt.2013.07.020. View

Wingard J, Majhail N, Brazauskas R, Wang Z, Sobocinski K, Jacobsohn D . Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011; 29(16):2230-9. PMC: 3107742. DOI: 10.1200/JCO.2010.33.7212. View

Curtis L, Grkovic L, Mitchell S, Steinberg S, Cowen E, Datiles M . NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD. Bone Marrow Transplant. 2014; 49(12):1513-20. PMC: 7665799. DOI: 10.1038/bmt.2014.188. View

Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P . Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant. 2005; 36(9):757-69. DOI: 10.1038/sj.bmt.1705140. View

Zeiser R, Blazar B . Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. N Engl J Med. 2017; 377(26):2565-2579. DOI: 10.1056/NEJMra1703472. View

Jagasia M, Greinix H, Arora M, Williams K, Wolff D, Cowen E . National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2014; 21(3):389-401.e1. PMC: 4329079. DOI: 10.1016/j.bbmt.2014.12.001. View

Hingorani S, Guthrie K, Schoch G, Weiss N, McDonald G . Chronic kidney disease in long-term survivors of hematopoietic cell transplant. Bone Marrow Transplant. 2007; 39(4):223-9. DOI: 10.1038/sj.bmt.1705573. View

Parikh C, Schrier R, Storer B, Diaconescu R, Sorror M, Maris M . Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. Am J Kidney Dis. 2005; 45(3):502-9. DOI: 10.1053/j.ajkd.2004.11.013. View

Zager R, OQuigley J, Zager B, Alpers C, Shulman H, Gamelin L . Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis. 1989; 13(3):210-6. DOI: 10.1016/s0272-6386(89)80054-x. View

10.

Inker L, Astor B, Fox C, Isakova T, Lash J, Peralta C . KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014; 63(5):713-35. DOI: 10.1053/j.ajkd.2014.01.416. View

11.

Abboud I, Peraldi M, Hingorani S . Chronic kidney diseases in long-term survivors after allogeneic hematopoietic stem cell transplantation: monitoring and management guidelines. Semin Hematol. 2012; 49(1):73-82. DOI: 10.1053/j.seminhematol.2011.10.008. View

12.

Hingorani S, Pao E, Stevenson P, Schoch G, Laskin B, Gooley T . Changes in Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation: A Prospective Cohort Study. Clin J Am Soc Nephrol. 2018; 13(6):866-873. PMC: 5989688. DOI: 10.2215/CJN.10630917. View

13.

Cohen E, Drobyski W, Moulder J . Significant increase in end-stage renal disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007; 39(9):571-2. DOI: 10.1038/sj.bmt.1705643. View

14.

Ando M, Ohashi K, Akiyama H, Sakamaki H, Morito T, Tsuchiya K . Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors. Nephrol Dial Transplant. 2009; 25(1):278-82. DOI: 10.1093/ndt/gfp485. View

15.

Hingorani S . Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatment. J Am Soc Nephrol. 2006; 17(7):1995-2005. DOI: 10.1681/ASN.2006020118. View

16.

Abboud I, Porcher R, Robin M, Peffault de Latour R, Glotz D, Socie G . Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009; 15(10):1251-7. DOI: 10.1016/j.bbmt.2009.05.016. View

17.

Sakellari I, Barbouti A, Bamichas G, Mallouri D, Kaloyannidis P, Fragidis S . GVHD-associated chronic kidney disease after allogeneic haematopoietic cell transplantation. Bone Marrow Transplant. 2013; 48(10):1329-34. DOI: 10.1038/bmt.2013.55. View

18.

Beyar-Katz O, Davila E, Zuckerman T, Fineman R, Haddad N, Okasha D . Adult Nephrotic Syndrome after Hematopoietic Stem Cell Transplantation: Renal Pathology is the Best Predictor of Response to Therapy. Biol Blood Marrow Transplant. 2016; 22(6):975-981. DOI: 10.1016/j.bbmt.2015.12.014. View

19.

Srinivasan R, Balow J, Sabnis S, Lundqvist A, Igarashi T, Takahashi Y . Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. Br J Haematol. 2005; 131(1):74-9. DOI: 10.1111/j.1365-2141.2005.05728.x. View

20.

Nieder M, McDonald G, Kida A, Hingorani S, Armenian S, Cooke K . National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage.... Biol Blood Marrow Transplant. 2011; 17(11):1573-84. PMC: 3215762. DOI: 10.1016/j.bbmt.2011.09.013. View